This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To provide safety and effectiveness outcomes at 12 months post-surgically for the ab interno transscleral gelatin stent in patients with advanced glaucoma refractory or intolerant of medical therapy.
All patients implanted with the gelatin stent either combined with cataract surgery or as a solo procedure between February 2017 and April 2018 and meeting eligibility criteria were included. Outcome measures included proportion of patients achieving a 20% reduction in intraocular pressure (IOP), proportions at or below 12, 15, and 18 mmHg, IOP, medication usage, needling rate, and adverse events.
The study included 92 eyes of 69 patients. Mean preoperative IOP and medications were 16.6 mmHg on 2.1 medications. Average visual field mean deviation was -13.7 dB. Half (48%) of the patients achieved the primary endpoint of 20% reduction while medication use decreased by -1.7 medications. The majority of patients at 12 months had IOP ≤ 18 mmHg on zero medications (74%) while 34% were medication free and had IOP ≤ 12 mmHg. Bleb needling was required for only 14% of patients. There were few adverse events (13% of eyes), the most common being BCVA loss and hyphema.
Eyes with advanced glaucoma despite maximum tolerated medical therapy can achieve lower target IOP on fewer medications following implantation with the gelatin microstent.
This presentation is from the session "SPS-105 Minimally Invasive Glaucoma Surgery: Viscocanalostomy, Combined Procedures, Outcomes" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.